Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European Association of Percutaneous Cardiovascular Interventions, and the Heart Failure Association of the ESC - Summary - MDSpire

Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European Association of Percutaneous Cardiovascular Interventions, and the Heart Failure Association of the ESC

  • By

  • Vassilios S Vassiliou

  • Vasiliki Tsampasian

  • Maria Luiza Luchian

  • Flavio D’Ascenzi

  • Fabrizio D’Ascenzo

  • Marc R Dweck

  • Javier Escaned

  • Sabiha Gati

  • Martin Halle

  • Konstantinos C Koskinas

  • Lis Neubeck

  • Michael Papadakis

  • Steffen E Petersen

  • Arsen Ristic

  • Marco Metra

  • Giuseppe Biondi-Zoccai

  • September 18, 2025

  • 0 min

Share

Objective:

To provide comprehensive guidance on cardiovascular prevention strategies across all stages of COVID-19, specifically addressing risks associated with acute infection, prior infection, Long COVID, reinfection, and post-vaccination events.

Key Findings:
  • COVID-19 can trigger and exacerbate cardiovascular complications during both acute and post-acute phases, including myocarditis, myocardial infarction, heart failure, and thrombotic events.
  • Long COVID may lead to persistent cardiovascular symptoms in over 20% of affected individuals.
  • Proactive cardiovascular prevention is essential for improving outcomes, especially in patients with elevated cardiac injury markers.
Interpretation:

The evolving nature of COVID-19 necessitates ongoing research to optimize preventive strategies and improve patient care, particularly for those with cardiovascular risks, highlighting the need for continuous adaptation of clinical practices.

Limitations:
  • The consensus may not cover all emerging evidence post-publication, which could affect the applicability of the recommendations.
  • Individualized preventive measures may vary across diverse populations, necessitating further research.
Conclusion:

The document emphasizes the need for tailored cardiovascular rehabilitation and lifestyle modifications to enhance patient outcomes in the context of COVID-19, advocating for personalized approaches.

Original Source(s)

Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European Association of Percutaneous Cardiovascular Interventions, and the Heart Failure Association of the ESC

  • by Vassilios S Vassiliou, Vasiliki Tsampasian, Maria Luiza Luchian, Flavio D’Ascenzi, Fabrizio D’Ascenzo, Marc R Dweck, Javier Escaned, Sabiha Gati, Martin Halle, Konstantinos C Koskinas, Lis Neubeck, Michael Papadakis, Steffen E Petersen, Arsen Ristic, Marco Metra, Giuseppe Biondi-Zoccai

  • September 18, 2025

Related Content

Heart failure risk prediction based on machine learning and interpretability analysis

Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial

The latest developments on Ebola, hepatitis B, long Covid